# Atezolizumab plus bevacizumab in advanced malignant peritoneal mesothelioma

Source: https://onco.cc/key-papers/paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021/  
OnCo record `paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In a small trial combining PD-L1 and VEGF blockade, four in ten patients with previously treated peritoneal mesothelioma responded, with responses lasting well over a year, the first dedicated prospective evidence for immunotherapy in this rare disease.

## Summary

Single-centre phase 2 study of 20 patients with advanced unresectable peritoneal mesothelioma progressing after platinum-pemetrexed, treated with atezolizumab and bevacizumab.

Objective response was 40 percent with a median duration of response of 12.8 months, one-year progression-free survival 61 percent and one-year overall survival 85 percent; biomarker analyses linked response to epithelial-mesenchymal transition and immune features.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Cancer Discovery
- Year: 2021
- DOI: 10.1158/2159-8290.CD-21-0331
- Authors: Raghav K, Liu S, Overman MJ, et al.
- Findings: Objective response 40 percent; median duration of response 12.8 months.; One-year overall survival 85 percent.
- What it means: Immunotherapy combinations, largely extrapolated from pleural trials, now have direct supporting data in peritoneal mesothelioma and are used after or instead of chemotherapy in unresectable disease.
- Caveats: Twenty patients at a single centre; no comparator.

## Sources

- Cancer Discov 2021: https://doi.org/10.1158/2159-8290.CD-21-0331
- PubMed: https://pubmed.ncbi.nlm.nih.gov/34261675/

## Connected records

- cancers: [Peritoneal mesothelioma](https://onco.cc/cancers/peritoneal-mesothelioma/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/)
- journals: [Cancer Discovery](https://onco.cc/journals/cancer-discovery/)

---
JSON: https://onco.cc/api/v1/entities/paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021.json